20 (AIDX) EBIT Margin (2025 - 2026)
20 posted quarterly EBIT Margin of 408.45% for Q1 2026, down 26902.0% year-on-year from N/an in Q1 2025, and down 192.95% on a QoQ basis from 139.43% in Q1 2025.
20 (AIDX) has 2 years of EBIT Margin data on file, last reported at 408.45% in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 16.24% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 28.97% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 6.17% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 21.42% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 10.04% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 19.94% |
| 10 | 20 | - | - | 62,884.00 | -408.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -408.45% |
| Mar 31, 2025 | -139.43% |